Enanta Pharmaceuticals, Inc. (ENTA) is listed on NASDAQ in the Manufacturing sector. This page tracks real-time ENTA price, technical indicators including RSI, MACD, and the 52-week range, plus fundamentals, earnings history, and recent insider trading activity.
Technical Analysis
RSI (14) 46.9 Neutral
Market Cap $392.0M
Volume 88.4K
Fundamentals — 10-Q Q2 2026
Revenue $35.8M
Net Income $-25.0M
EPS $-0.87
Operating Margin -64.6%
Net Margin -70.0%
P/E Ratio -15.5x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Luu Brendan | Chief Business Officer | Sell | 1,394 | $14.23 | $19,837 | 2025 Dec 5 |
| Rottinghaus Scott T. | Chief Medical Officer | Sell | 798 | $14.23 | $11,356 | 2025 Dec 5 |
| Capps Kathleen S. | Officer | Sell | 323 | $14.23 | $4,596 | 2025 Dec 5 |
| Luly Jay R. | President and CEO | Sell | 4,743 | $14.23 | $67,493 | 2025 Dec 5 |
| Kieffer Tara Lynn | Chief Product Strategy Officer | Sell | 2,106 | $14.23 | $29,968 | 2025 Dec 5 |
| Or Yat Sun | Chief Scientific Officer | Sell | 2,390 | $14.23 | $34,010 | 2025 Dec 5 |
| Trout Harry R. III | Officer | Sell | 542 | $14.23 | $7,713 | 2025 Dec 5 |
| Capps Kathleen S. | Officer | Sell | 207 | $13.96 | $2,890 | 2025 Dec 2 |
| Trout Harry R. III | Officer | Sell | 380 | $13.96 | $5,305 | 2025 Dec 2 |
| Luly Jay R. | President and CEO | Buy | 45,000 | $5.69 | $256,050 | 2025 Feb 12 |
| Rottinghaus Scott T. | Chief Medical Officer | Sell | 866 | $8.06 | $6,980 | 2024 Dec 6 |
| Luly Jay R. | President and CEO | Sell | 5,142 | $8.06 | $41,445 | 2024 Dec 6 |
| Or Yat Sun | Chief Scientific Officer | Sell | 2,591 | $8.06 | $20,883 | 2024 Dec 6 |
| Luu Brendan | Chief Business Officer | Sell | 2,283 | $8.06 | $18,401 | 2024 Dec 6 |
| Kieffer Tara Lynn | Chief Product Strategy Officer | Sell | 2,283 | $8.06 | $18,401 | 2024 Dec 6 |
| Mellett Paul J | Chief Fin. & Admin Officer | Sell | 2,591 | $8.06 | $20,883 | 2024 Dec 6 |
| Rottinghaus Scott T. | Chief Medical Officer | Sell | 11,945 | $15.97 | $190,747 | 2024 Jul 15 |
| Kieffer Tara Lynn | Chief Product Strategy Officer | Sell | 7,266 | $12.33 | $89,590 | 2024 Jun 17 |
| Vance Terry | Director | Sell | 15,295 | $9.12 | $139,490 | 2023 Dec 13 |
| Mellett Paul J | Sr. VP, Finance & Admin. & CFO | Sell | 2,412 | $9.63 | $23,228 | 2023 Dec 5 |
Take ENTA further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put ENTA in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Enanta Pharmaceuticals, Inc. next reports.
Set alerts on ENTA
Get notified when Enanta Pharmaceuticals, Inc. hits your price targets or technical conditions are met.
Get Started Free